Bruce L. Downey was named chief executive officer and chairman, succeeding the generic drug company's founder, Edwin A. Cohen, who retires Feb. 24.
Mr. Downey, 46, will continue as president, a post he assumed last year.
Mr. Cohen said he has considered changing his role at the company for some time and will now do so because of the management team in place.
Mr. Cohen, 61, continues as a consultant and vice chairman.
